Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotronex risk management progress

Executive Summary

FDA's Drug Safety & Risk Management Advisory Committee will receive a progress report May 5 on the risk management program for GlaxoSmithKline's Lotronex. The committee is also slated to discuss medication errors relating to the labeling and packaging of drug products in low density polyethylene (LDPE) plastic vials. The meeting will be held at the CDER Advisory Committee conference room, 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m. [To 1watch a webcast of this meeting, go to FDAAdvisoryCommittee.com]...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS043627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel